Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Praxis Precision Medicines’s Essential1 Study Evaluating Ulixacaltamide (PRAX-944) For Essential Tremor Did Not Reach Statistical Significance On Primary Endpoint, Change From Baseline To Day 56 In The Modified Activities Of Daily Living (mADL) Score

Ulixacaltamide demonstrated improvement in modified Activities of Daily Living (mADL) primary efficacy endpoint relative to placebo that did not reach statistical significance (p=0.126), and achieved nominal

PRAX

Read More

Incannex Has Engaged Catalent To Develop And Manufacture A cGMP-grade Psilocybin Drug Product For Use In Incannex’s Proprietary Psilocybin-assisted Psychotherapy Drug Development Program And, Potential Wider Commercial Use

Commencing development and manufacture of a psilocybin drug product follows an internal analysis of the interim data from the PsiGAD phase 2 clinical trial, giving Incannex confidence to proceed with formulation

CTLT